Contribution of Neuroepigenetics to Huntington's Disease

Overview

Journal Front Hum Neurosci

Specialty Neurology

Date 2017 Feb 15

PMID 28194101

Citations 24

Authors

Laetitia Francelle

Caroline Lotz

Tiago Outeiro

Emmanuel Brouillet

Karine Merienne

Affiliations

Soon will be listed here.

Abstract

Unbalanced epigenetic regulation is thought to contribute to the progression of several neurodegenerative diseases, including Huntington's disease (HD), a genetic disorder considered as a paradigm of epigenetic dysregulation. In this review, we attempt to address open questions regarding the role of epigenetic changes in HD, in the light of recent advances in neuroepigenetics. We particularly discuss studies using genome-wide scale approaches that provide insights into the relationship between epigenetic regulations, gene expression and neuronal activity in normal and diseased neurons, including HD neurons. We propose that cell-type specific techniques and 3D-based methods will advance knowledge of epigenome in the context of brain region vulnerability in neurodegenerative diseases. A better understanding of the mechanisms underlying epigenetic changes and of their consequences in neurodegenerative diseases is required to design therapeutic strategies more effective than current strategies based on histone deacetylase (HDAC) inhibitors. Researches in HD may play a driving role in this process.

Citing Articles

Ethylene Signaling in Regulating Plant Growth, Development, and Stress Responses.

Wang X, Wen H, Suprun A, Zhu H Plants (Basel). 2025; 14(3).

PMID: 39942870 PMC: 11820588. DOI: 10.3390/plants14030309.

An Emerging Role for Enhancer RNAs in Brain Disorders.

Patel A, Dharap A Neuromolecular Med. 2024; 26(1):7.

PMID: 38546891 PMC: 11263973. DOI: 10.1007/s12017-024-08776-3.

Retinal dysfunction in Huntington's disease mouse models concurs with local gliosis and microglia activation.

Cano-Cano F, Martin-Loro F, Gallardo-Orihuela A, Gonzalez-Montelongo M, Ortuno-Miquel S, Hervas-Corpion I Sci Rep. 2024; 14(1):4176.

PMID: 38378796 PMC: 10879138. DOI: 10.1038/s41598-024-54347-8.

Investigating Neuron Degeneration in Huntington's Disease Using RNA-Seq Based Transcriptome Study.

Sneha N, Dharshini S, Taguchi Y, Gromiha M Genes (Basel). 2023; 14(9).

PMID: 37761940 PMC: 10530489. DOI: 10.3390/genes14091801.

A minimal region of the HSP90AB1 promoter is suitable for ubiquitous expression in different somatic tissues with applicability for gene therapy.

Mielcarek M, Isalan M Front Mol Biosci. 2023; 10:1175407.

PMID: 37138658 PMC: 10149993. DOI: 10.3389/fmolb.2023.1175407.

References

Federman N, Fustinana M, Romano A . Histone acetylation is recruited in consolidation as a molecular feature of stronger memories. Learn Mem. 2009; 16(10):600-6. DOI: 10.1101/lm.1537009. View

Becanovic K, Pouladi M, Lim R, Kuhn A, Pavlidis P, Luthi-Carter R . Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum Mol Genet. 2010; 19(8):1438-52. PMC: 2846159. DOI: 10.1093/hmg/ddq018. View

Hogarth P, Lovrecic L, Krainc D . Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov Disord. 2007; 22(13):1962-4. DOI: 10.1002/mds.21632. View

Jeltsch A . Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol. 2006; 301:203-25. DOI: 10.1007/3-540-31390-7_7. View

Igarashi S, Morita H, Bennett K, Tanaka Y, Engelender S, Peters M . Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport. 2003; 14(4):565-8. DOI: 10.1097/00001756-200303240-00007. View

von Schimmelmann M, Feinberg P, Sullivan J, Ku S, Badimon A, Duff M . Polycomb repressive complex 2 (PRC2) silences genes responsible for neurodegeneration. Nat Neurosci. 2016; 19(10):1321-30. PMC: 5088783. DOI: 10.1038/nn.4360. View

Steffan J, Bodai L, PALLOS J, Poelman M, McCampbell A, Apostol B . Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001; 413(6857):739-43. DOI: 10.1038/35099568. View

Valor L . Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease. Int J Biochem Cell Biol. 2015; 67:45-8. DOI: 10.1016/j.biocel.2015.04.009. View

Zovkic I, Guzman-Karlsson M, Sweatt J . Epigenetic regulation of memory formation and maintenance. Learn Mem. 2013; 20(2):61-74. PMC: 3549063. DOI: 10.1101/lm.026575.112. View

10.

Dietz K, Di Stefano L, Maher R, Zhu H, MacDonald M, Gusella J . The Drosophila Huntington's disease gene ortholog dhtt influences chromatin regulation during development. Hum Mol Genet. 2014; 24(2):330-45. DOI: 10.1093/hmg/ddu446. View

11.

Sharma S, Taliyan R . Targeting histone deacetylases: a novel approach in Parkinson's disease. Parkinsons Dis. 2015; 2015:303294. PMC: 4324954. DOI: 10.1155/2015/303294. View

12.

Luthi-Carter R, Strand A, Peters N, Solano S, Hollingsworth Z, Menon A . Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000; 9(9):1259-71. DOI: 10.1093/hmg/9.9.1259. View

13.

Giralt A, Puigdellivol M, Carreton O, Paoletti P, Valero J, Parra-Damas A . Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum Mol Genet. 2011; 21(6):1203-16. DOI: 10.1093/hmg/ddr552. View

14.

DiFiglia M, Sapp E, Chase K, Davies S, Bates G, Vonsattel J . Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997; 277(5334):1990-3. DOI: 10.1126/science.277.5334.1990. View

15.

Feng J, Shao N, Szulwach K, Vialou V, Huynh J, Zhong C . Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. Nat Neurosci. 2015; 18(4):536-44. PMC: 4617315. DOI: 10.1038/nn.3976. View

16.

Thomas B, Matson S, Chopra V, Sun L, Sharma S, Hersch S . A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal Biochem. 2013; 436(2):112-20. PMC: 4090024. DOI: 10.1016/j.ab.2013.01.035. View

17.

Lee J, Hwang Y, Kim K, Kowall N, Ryu H . Epigenetic mechanisms of neurodegeneration in Huntington's disease. Neurotherapeutics. 2013; 10(4):664-76. PMC: 3805871. DOI: 10.1007/s13311-013-0206-5. View

18.

Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, Pages C . Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J. 2007; 22(4):1083-93. DOI: 10.1096/fj.07-9814. View

19.

Brami-Cherrier K, Roze E, Girault J, Betuing S, Caboche J . Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. J Neurochem. 2009; 108(6):1323-35. DOI: 10.1111/j.1471-4159.2009.05879.x. View

20.

Feng J, Zhou Y, Campbell S, Le T, Li E, Sweatt J . Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci. 2010; 13(4):423-30. PMC: 3060772. DOI: 10.1038/nn.2514. View